A new clinical trial involving nafarelin was posted on June 4, 2026. The study, titled "Intranasal Nafarelin For Triggering Oocyte Maturation," is registered under identifier NCT06763926.
The trial is listed as Phase 4 and its current status is not yet recruiting. According to the registration, the study will examine intranasal nafarelin's use in triggering oocyte maturation.
No results, outcomes, or efficacy data have been posted for this trial at this time. As a not yet recruiting study, enrollment has not begun and no participant data are currently available.
Nafarelin remains an approved compound, and this Phase 4 study represents ongoing clinical evaluation within its approved use context. Further details, including recruitment timelines and study design specifics, may be updated as the trial progresses through registration channels.
Interested readers can track updates to this trial through its official registration page. For background on nafarelin, including its approved indications and general profile, readers can consult the compound overview.